Provectus Biopharmaceuticals (PVCT) CEO granted 8% note with stock conversion

Rhea-AI Filing Summary

Provectus Biopharmaceuticals CEO Edward Pershing, who also serves as a director, reported receiving an 8% unsecured convertible promissory note on February 5, 2026. The note can be converted into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.

Under the terms described, each share of Series D-1 preferred is convertible into 10 shares of common stock. The Series D-1 preferred will automatically convert into common stock on December 31, 2028, unless it is converted earlier under its certificate of designation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	8% Unsecured Convertible Promissory Note	0	$0.00	--

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 shares (Direct)

Footnotes (1)

1. The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2025 Financing. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TN 37929

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	02/05/2026		A		$10,000		02/05/2026	02/05/2027	Series D-1 Convertible Preferred Stock(1)(2)	3,495	$0	$1,290,000	D

Explanation of Responses:

1. The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2025 Financing.

2. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

	/s/ Edward Pershing	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PVCT CEO Edward Pershing report?

Edward Pershing reported receiving an 8% unsecured convertible promissory note. The Form 4 shows the note was acquired on February 5, 2026 and is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share.

How does the 8% unsecured convertible note for PVCT convert into stock?

The 8% note can be voluntarily converted into Series D-1 preferred shares at $2.862 per share. If not converted earlier, the outstanding principal and interest automatically convert into Series D-1 preferred twelve months after the note’s issue date.

What is the conversion ratio from PVCT Series D-1 preferred to common stock?

Each Series D-1 preferred share converts into 10 common shares. The filing states that every share of Series D-1 Convertible Preferred Stock can be exchanged for 10 shares of Provectus Biopharmaceuticals’ common stock, providing a defined equity conversion structure.

When will PVCT Series D-1 preferred shares automatically convert to common stock?

Series D-1 preferred shares automatically convert on December 31, 2028. They will turn into common stock on that date unless they are converted earlier according to the terms in the Certificate of Designation governing the Series D-1 preferred.

What role does Edward Pershing hold at Provectus Biopharmaceuticals (PVCT)?

Edward Pershing is both CEO and a director of Provectus Biopharmaceuticals. The Form 4 identifies him as an officer with the title Chief Executive Officer and also notes his status as a member of the company’s board of directors.

What interest rate does the PVCT unsecured convertible promissory note carry?

The unsecured convertible promissory note carries an 8% interest rate. This interest accrues while the note is outstanding and, along with principal, can be converted into Series D-1 preferred stock at $2.862 per share under the disclosed terms.